Embecta reports Q4 FY2022 net loss $17.2M; FY2023 guidance revenue $1,050-$1,073M

Embecta Corp.

Q4 revenue $274.6M, down 8.7% reported; net loss $17.2M vs income $97.1M prior year, includes $58.9M impairment.
FY2022 revenue $1,129.5M, down 3.1%; net income $223.6M vs $414.8M; adjusted EBITDA margin 40.7% vs 48.5%.
Quarterly dividend $0.15/share declared, payable Jan 11, 2023 to holders of record Dec 30, 2022.
Preliminary FY2023 guidance: revenue $1,050-$1,073M (down 5-7% reported); adj. diluted EPS $1.75-$2.00.
Entered co-promotion agreement with Intuity Medical for POGO Automatic blood glucose monitor in U.S.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Embecta Corp. reported the twelve months ended September 30, 2022 results: revenue $1,129.5 million, net income $223.6 million.

Period: the twelve months ended September 30, 2022
Revenue: $1,129.5 million
Net income: $223.6 million
Result: reported results

Exact text from the filing

Twelve Months Ended September 30 Fiscal Year 2022 Financial Highlights : • Revenues of $1,129.5 million, down 3.1% on a reported basis; down 0.5% on a constant currency basis

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Embecta Corp. reported the three months ended September 30, 2022 results: revenue $274.6 million, net income $(17.2) million.

Period: the three months ended September 30, 2022
Revenue: $274.6 million
Net income: $(17.2) million
Result: reported results

Exact text from the filing

Fourth Quarter Fiscal Year 2022 Financial Highlights : • Revenues of $274.6 million, down 8.7% on a reported basis; down 4.2% on a constant currency basis

View on SEC.gov

Browse all earnings releases →

Embecta Corp. filing history →

Source: SEC EDGAR

accession 0001872789-22-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.